Bryan Zair represents publicly traded and privately held U.S., foreign, and multinational clients on a broad range of transactional and corporate matters, focusing primarily in the areas of M&A, joint ventures, strategic alliances, collaborations, and similar arrangements, as well as other complex commercial arrangements including licensing, distribution, technology transfer, development, and supply agreements.He also counsels clients on general corporate law matters, including corporate governance and compliance.
Bryan's transactional experience spans a wide range of industries, including manufacturing, chemicals, automotive, life sciences, biotechnology, renewable energy, health care, pharmaceuticals, information technology, and agriculture.
Bryan is author of the chapter "Best Practices In Implementing Corporate Divestitures" in Managing Corporate Divestiture Transactions (December 2013).
GfK sells animal and crop health division
Jones Day is representing GfK SE, a market research provider, in connection with the sale of its global animal and crop health division to a consortium consisting of Inflexion, a private equity investor, and the current management.
The following represents experience acquired prior to joining Jones Day.
Represented The Dow Chemical Company in connection with a variety of corporate transactional matters throughout the world, including the formation of America Styrenics, a joint venture with Chevron Phillips Chemical Company involving assets from their respective polystyrene and styrene monomer businesses; the sale of Dexco Polymers, a joint venture of Dow and ExxonMobil Chemical Company, to TSRC Corporation; and the formation of a joint venture with Mitsui & Co. for the production and sale in Brazil of biopolymers made from renewable, sugarcane-derived ethanol.
Represented Dow AgroSciences in connection with a variety of corporate transactional matters throughout the world, including a collaboration arrangement with World Wide Wheat for the development and commercialization of advanced germplasm and traits in wheat; the sale of its Vikane and ProFume businesses to Douglas Products and Packaging Company; the sale of its European Mancozeb business to Indofil Industries Limited; its acquisition of an ownership interest in Tecnoseeds Brasil Sementes & Serviços, as part of the formation of a joint venture with a subsidiary of Asociados Don Mario for the processing of hybrid corn seeds in Brazil; and its acquisition of certain assets relating to the hybrid seed business of Renze Hybrids.
Represented Baxter Healthcare Corporation in connection with the sale of its U.S. generic injectables business to West-Ward Pharmaceutical Corp., the U.S.-based subsidiary of Hikma Pharmaceuticals for a purchase price of $112 million.
Represented the founders of CDMI, a privately held drug benefit management company, in connection with their sale of 100 percent of the equity interests in CDMI to Magellan Health Services for a purchase price (including potential contingent payments) of $375 million.
Represented United Stars Holdings in a series of asset and stock acquisitions throughout the Midwest United States, including the acquisition of 100 percent of the stock of Waukesha Foundry from FCF Partners; the acquisition of certain assets relating to the precision machining and grinding business of Line Craft Tool Company; the acquisition of certain assets relating to the high-quality castings business of Manchester Metals; and the acquisition of certain assets relating to the industrial gearing business of GearTec.
Publications Prior to Jones Day
"Best Practices In Implementing Corporate Divestitures," Managing Corporate Divestiture Transactions (Aspatore Books, December 2013)